A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
Ng M, Chen S, Ong WS, Balachander A, Seet A, Yeong J, Sutiman N, Lim TKH, Lee B, Guo YA, Leong WF, Lee SS, Lam J, Choo SP, Skanderup AJ, Biswas SK, Tai D, Chowbay B.
Ng M, et al. Among authors: chowbay b.
Int J Cancer. 2022 Aug 1;151(3):435-449. doi: 10.1002/ijc.34021. Epub 2022 May 6.
Int J Cancer. 2022.
PMID: 35415893
Clinical Trial.